Danilov on BTK Inhibition for Relapsed/Refractory CLL
Alexey Danilov, MD, a hematologist oncologist at the City of Hope Comprehensive Cancer Center, discusses treatment options for relapsed/refractory chronic lymphocytic leukemia.
Alexey Danilov, MD, a hematologist oncologist at the City of Hope Comprehensive Cancer Center, discusses treatment options for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
According to Danilov, very good results have been seen with Bruton’s tyrosine kinase (BTK) inhibitors, with some patients staying on them for 5-6 years before progression. This is true even in those with high-risk disease and in patients with TP53 mutations. In comparison, patients on chemoimmunotherapy tend to progress after a year.
BTK inhibitors help to delay when you have to being talking about R/R disease, says Danilov. However, questions still remain around progression in regard to BTK inhibitors. There are enough data on the use of second-line BTKs, according to Danilov. Additionally, if a patient progresses on the BCL-2 inhibitor, venetoclax (Venclexta), a BTK inhibitor may be a useful treatment option. In the case of progression on a BTK inhibitor, the reverse strategy of moving to a BCL-2 inhibitor is viable.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
FDA Approves Liso-Cel in Relapsed or Refractory CLL/SLL
March 15th 2024The current indication of lisocabtagene maraleucel has been expanded to include adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received a prior BTK inhibitor and B-cell lymphoma 2 inhibitor.
Read More
